Nexentis Technologies NXTS
NASDAQ NXTS
$1.69 +0.02 (+1.20%)
At close: Sep 9, 2026 · 4:00 PM EDT

Nexentis Technologies (NXTS) Non Operating Interest Expenses (2024)

Nexentis Technologies (NXTS) posted Non Operating Interest Expenses of $12171.0 for Q1 2024.

Analysis

Nexentis Technologies (NXTS) Non Operating Interest Expenses (2024) Analysis & Trends

Nexentis Technologies has reported Non Operating Interest Expenses for 1 years, with the latest figure at $12171.0 in Q1 2024.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Nexentis Technologies 1.40 Mn -7.48 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 12,171.00